

Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock

PALO ALTO, Calif., August 18, 2016 /PR Newswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases, today announced the pricing of its underwritten public offering of 1,250,000 shares of its common stock at a price to the public of \$16.00 per share, before underwriting discounts and commissions. All of the shares of common stock to be sold in the offering are to be sold by Eiger. The gross proceeds from the offering to Eiger are expected to be \$20.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Eiger. In addition, Eiger has granted to the underwriters a 30-day option to purchase up to 187,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions.

Eiger intends to use the net proceeds of the offering to fund the clinical development of its portfolio of four product candidates, and for working capital and other general corporate purposes.

Jefferies LLC is acting as sole book-running manager for the offering. Oppenheimer & Co. Inc. and Wedbush PacGrow are acting as co-managers for the offering. The offering is expected to close on or about August 23, 2016, subject to customary closing conditions.

A shelf registration statement relating to the shares of common stock offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on June 17, 2016 and declared effective by the SEC on August 4, 2016. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC's website at www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by email at Prospectus_Department@Jefferies.com, or by phone at (877) 547-6340.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Eiger BioPharmaceuticals, Inc.

Eiger is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare diseases. The company has built a diverse portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which an effective therapy is urgently needed.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding the anticipated public offering, anticipated use of proceeds, our strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives, intentions, beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as "anticipate," "believe," "could," "estimate," "expect," "forecast,"

“intend,” “may,” “plan,” “potential,” “project,” “target,” “will” and other words and terms of similar meaning. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Eiger makes, including uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and the risks described in the “Risk Factors” sections in the Annual Report on Form 10-K for the period ended December 31, 2015 and Eiger’s periodic reports filed with the SEC. Eiger does not assume any obligation to update any forward-looking statements, except as required by law.

Contact:

Investors/Media:

Jim Welch

Eiger BioPharmaceuticals, Inc.

Phone: (650) 279-9845

Email: jwelch@eigerbio.com